

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 February 2022 (17.02.2022)



(10) International Publication Number
WO 2022/035900 A1

(51) International Patent Classification:

A61K 48/00 (2006.01) C12N 15/864 (2006.01)

(21) International Application Number:

PCT/US2021/045443

(22) International Filing Date:

10 August 2021 (10.08.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/063,852 10 August 2020 (10.08.2020) US

(71) Applicant: **PREVAIL THERAPEUTICS, INC.**
[US/US]; 430 East 29th Street, Suite 940, New York, New
York 10016 (US).

(72) Inventors; and

(71) Applicants: **ABELIOVICH, Asa** [US/US]; 20 East 35th
Street, Apt. 15E, New York, New York 10016 (US).
SEVIGNY, Jeffrey [US/CH]; 169 Hohestrasse, 4014 Ober-
wil (CH). **LEWIS, Travis** [US/US]; 515 East 72nd St., Apt
30B, New York, New York 10021 (US). **USPENSKAYA,**
Olga [FR/FR]; 22 chemin de Bretagne, 92130 Issy-les-
Moulineaux (FR).

(74) Agent: **ELRIFI, Ivor** et al.; Cooley LLP, 1299 Pennsyl-
vania Ave., Suite 700, Washington, District of Columbia
20004 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: GENE THERAPIES FOR NEURODEGENERATIVE DISORDERS

(57) Abstract: The disclosure relates to compositions and methods for treatment of neurodegenerative disorders, such as fronto-temporal dementia (FTD). The disclosure provides methods of treating FTD by administering expression constructs comprising a transgene encoding programulin or a portion thereof to a subject in need thereof.

WO 2022/035900 A1